{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:19:27Z","timestamp":1761513567791,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Siemens Healthcare, Inc"},{"name":"GTx, Inc"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.clbc.2018.11.010","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T12:56:12Z","timestamp":1543236972000},"page":"146-155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET\/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade"],"prefix":"10.1016","volume":"19","author":[{"given":"Heather A.","family":"Jacene","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trisha","family":"Youn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela J.","family":"DiPiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiani","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Chun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Franchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hina","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer R.","family":"Bellon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7418-6405","authenticated-orcid":false,"given":"Laura","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Schlosnagle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4752-0161","authenticated-orcid":false,"given":"Faina","family":"Nakhlis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Rosenbluth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8939-1348","authenticated-orcid":false,"given":"Eren","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"Overmoyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2018.11.010_bib1","first-page":"291","article-title":"Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program","volume":"74","author":"Levine","year":"1985","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2018.11.010_bib2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/annonc\/mdq345","article-title":"International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment","volume":"22","author":"Dawood","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2018.11.010_bib3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/jso.2930210111","article-title":"Estrogen receptor status in inflammatory breast carcinoma","volume":"21","author":"Harvey","year":"1982","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.clbc.2018.11.010_bib4","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1158\/1078-0432.CCR-05-2248","article-title":"Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype","volume":"12","author":"Nguyen","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2018.11.010_bib5","first-page":"1437","article-title":"International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference","volume":"9","author":"Ueno","year":"2018","journal-title":"J\u00a0Cancer"},{"key":"10.1016\/j.clbc.2018.11.010_bib6","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/S0360-3016(02)04201-3","article-title":"Ten-year outcome after combined modality therapy for inflammatory breast cancer","volume":"55","author":"Harris","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clbc.2018.11.010_bib7","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/cncr.21726","article-title":"Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy","volume":"106","author":"Hennessy","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2018.11.010_bib8","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.1999.17.2.460","article-title":"Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy","volume":"17","author":"Kuerer","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2018.11.010_bib9","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1245\/s10434-017-5903-6","article-title":"The impact of residual disease after preoperative systemic therapy on clinical outcomes in patients with inflammatory breast cancer","volume":"24","author":"Nakhlis","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2018.11.010_bib10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.6004\/jnccn.2017.0044","article-title":"NCCN Guidelines Insights: Breast Cancer, Version 1.2017","volume":"15","author":"Gradishar","year":"2017","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clbc.2018.11.010_bib11","doi-asserted-by":"crossref","first-page":"682","DOI":"10.6004\/jnccn.2017.0072","article-title":"NCCN Guidelines Update: Evolving Radiation Therapy Recommendations for Breast Cancer","volume":"15","author":"Salerno","year":"2017","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clbc.2018.11.010_bib12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s00259-013-2595-4","article-title":"(1)(8)F-FDG PET\/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations","volume":"41","author":"Cochet","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clbc.2018.11.010_bib13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2967\/jnumed.112.106864","article-title":"18F-FDG PET\/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging","volume":"54","author":"Groheux","year":"2013","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.clbc.2018.11.010_bib14","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.ejso.2013.08.025","article-title":"Can FDG-PET\/CT predict early response to neoadjuvant chemotherapy in breast cancer?","volume":"39","author":"Andrade","year":"2013","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.clbc.2018.11.010_bib15","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.2967\/jnumed.112.119271","article-title":"18F-FDG PET\/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO","volume":"54","author":"Gebhart","year":"2013","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.clbc.2018.11.010_bib16","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1007\/s00259-012-2211-z","article-title":"Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy","volume":"39","author":"Koolen","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clbc.2018.11.010_bib17","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1002\/cncr.24534","article-title":"18F-fluorodeoxyglucose positron emission tomography\/computed tomography (FDG-PET\/CT) imaging in the staging and prognosis of inflammatory breast cancer","volume":"115","author":"Alberini","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2018.11.010_bib18","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00268-003-6893-z","article-title":"18-Fluorodeoxyglucose-positron emission tomography in inflammatory breast cancer","volume":"27","author":"Baslaim","year":"2003","journal-title":"World J Surg"},{"key":"10.1016\/j.clbc.2018.11.010_bib19","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.acra.2012.01.001","article-title":"Semiquantitative analysis of maximum standardized uptake values of regional lymph nodes in inflammatory breast cancer: is there a reliable threshold for differentiating benign from malignant?","volume":"19","author":"Carkaci","year":"2012","journal-title":"Acad Radiol"},{"key":"10.1016\/j.clbc.2018.11.010_bib20","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2967\/jnumed.108.056010","article-title":"Retrospective study of 18F-FDG PET\/CT in the diagnosis of inflammatory breast cancer: preliminary data","volume":"50","author":"Carkaci","year":"2009","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.clbc.2018.11.010_bib21","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s00259-013-2506-8","article-title":"(18)F-FDG PET\/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy","volume":"40","author":"Carkaci","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clbc.2018.11.010_bib22","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2967\/jnumed.115.158287","article-title":"18F-FDG PET\/CT to predict response to neoadjuvant chemotherapy and prognosis in inflammatory breast cancer","volume":"56","author":"Champion","year":"2015","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.clbc.2018.11.010_bib23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10549-007-9671-z","article-title":"Inflammatory breast cancer: PET\/CT, MRI, mammography, and sonography findings","volume":"109","author":"Yang","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2018.11.010_bib24","first-page":"66","article-title":"18F-FDG PET-CT imaging in the neoadjuvant setting for stages II-III breast cancer: association of locoregional SUVmax with classical prognostic factors","volume":"58","author":"Garcia Garcia-Esquinas","year":"2014","journal-title":"Q\u00a0J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clbc.2018.11.010_bib25","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s00259-012-2244-3","article-title":"Semi-quantitative lymph node assessment of (18)F-FDG PET\/CT in locally advanced breast cancer: correlation with biological prognostic factors","volume":"40","author":"Garcia Vicente","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clbc.2018.11.010_bib26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.breast.2012.05.009","article-title":"Is [18F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer?","volume":"22","author":"De Cicco","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2018.11.010_bib27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/path.1515","article-title":"Immunophenotypic analysis of inflammatory breast cancers: identification of an \u2018inflammatory signature\u2019","volume":"202","author":"Charafe-Jauffret","year":"2004","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.clbc.2018.11.010_bib28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000152938","article-title":"Clinicopathological features of inflammatory versus noninflammatory locally advanced nonmetastatic breast cancer","volume":"29","author":"Brouwers","year":"2008","journal-title":"Tumour Biol"},{"issue":"Suppl 1","key":"10.1016\/j.clbc.2018.11.010_bib29","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J\u00a0Nucl Med"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820918305081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820918305081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:16:54Z","timestamp":1761513414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820918305081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1526820918305081"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2018.11.010","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET\/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2018.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}